Results 161 to 170 of about 1,612,068 (309)

Role of FK506 binding protein 51 in central nervous system diseases. [PDF]

Front Mol Neurosci
Peng H, Wei Y, Qiu Y, Bi R, Zeng L, Hu B, Li Y.   +6 more
europepmc   +1 more source

Movement Disorders in Aicardi–Goutières Syndrome and Response to Immunomodulation

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT This study characterizes movement disorders and treatment responses in seven children with Aicardi–Goutières syndrome (AGS). We retrospectively evaluated motor phenotypes, neuroimaging, and interferon signatures in patients treated with baricitinib or anifrolumab. Spasticity affected all patients, while dystonia was present in 4/7.
Enrique Gonzalez Saez‐Diez, Monica Ferrer Socorro, Kathryn Yang, Nicole Battaglia, Zainab Zaman, Mariko Bennett, Adeline Vanderver, Pui Y. Lee, Lauren A. Henderson, Milena M. Andzelm, Darius Ebrahimi‐Fakhari   +10 more
wiley   +1 more source

Mitochondria-Targeted Nanosystems in the Treatment of Central Nervous System Diseases. [PDF]

Int J Nanomedicine
Zhang X, Chen J, Wan B, Zheng Y, Chen X.
europepmc   +1 more source

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source

The Mechanisms and Application Prospects of Astrocyte Reprogramming into Neurons in Central Nervous System Diseases. [PDF]

Curr Neuropharmacol
Qin R, Lai X, Xu W, Qin Q, Liang X, Xie M, Chen L.   +6 more
europepmc   +1 more source

Anti‐CD19 CAR T Cells in Autoimmune Encephalitis: Inflammation Controlled, Neurodegeneration Unchecked?

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Just recently, successful chimeric antigen receptor (CAR) T cell therapy was reported in the first patient with refractory, anti‐diacylglycerol lipase alpha (DAGLA) antibody‐mediated autoimmune encephalitis, achieving partial clinical remission.
Dimitrios Mougiakakos, Marwa Al‐Dubai, Denise Walther, Dominic Borie, Jan D. Lünemann, Marc Pawlitzki, Sven G. Meuth, Solveig Henneicke, Stefan Vielhaber, Stefanie Schreiber   +9 more
wiley   +1 more source

Corrigendum: MELK Inhibition Effectively Suppresses Growth of Glioblastoma and Cancer Stem-Like Cells by Blocking AKT and FOXM1 Pathways

Frontiers in Oncology, 2022
Xu Zhang, Xu Zhang, Xu Zhang, Jie Wang, Jie Wang, Jie Wang, Yifeng Wang, Yifeng Wang, Guanzheng Liu, Huan Li, Jiefeng Yu, Runqiu Wu, Jun Liang, Rutong Yu, Rutong Yu, Xuejiao Liu, Xuejiao Liu   +16 more
doaj   +1 more source

Exploring the Neuroprotective Potential of <i>Astragalus membranaceus</i> in Central Nervous System Diseases. [PDF]

Biomolecules
Sang J, Gao J, Zuo H, Yu H, Qin Y, Hu J, Hao F.   +6 more
europepmc   +1 more source

CAR T‐Cell Therapy in Neurology: A Scoping Review of Neuro‐Oncology, Autoimmune Diseases & Neurotoxicity

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Chimeric antigen receptor (CAR) T‐cell therapy has been investigated in neurological diseases, encompassing both central nervous system malignancies and autoimmune disorders, thereby extending its application beyond hematological cancers.
Omar Alqaisi, Mohammed Dibas, Patricia Tai, Ala Dibas, Osama Souied, Suhair Al‐Ghabeesh   +5 more
wiley   +1 more source

Study on the final diagnosis of nervous system diseases with psychiatric symptoms as manifestation onset. [PDF]

BMC Psychiatry
Li B, Guo W, Shang X.
europepmc   +1 more source